Oren Gilad
Amministratore Delegato presso APREA THERAPEUTICS, INC.
Patrimonio netto: 1 M $ in data 30/06/2024
Posizioni attive di Oren Gilad
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| APREA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/05/2022 | - |
| Amministratore Delegato | 29/06/2022 | - | |
| Presidente | 01/05/2022 | - |
Storia della carriera di Oren Gilad
Precedenti posizioni note di Oren Gilad
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Atrin Pharmaceuticals LLC
 Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Direttore/Membro del Consiglio | 01/01/2011 | 01/01/2022 |
| Amministratore Delegato | 01/01/2011 | 01/01/2022 | |
| Fondatore | 01/01/2011 | 01/01/2022 | |
| Presidente | 01/01/2011 | 01/01/2022 | |
Atrin Pharmaceuticals, Inc.
 Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Amministratore Delegato | 01/01/2011 | 01/01/2022 |
| Fondatore | 01/01/2011 | 01/01/2022 | |
| Presidente | 01/01/2011 | 01/01/2022 |
Formazione di Oren Gilad
| University of Pennsylvania | Doctorate Degree |
| University of California, Davis | Doctorate Degree |
| The Hebrew University of Jerusalem | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
| Israele | 2 |
Posizioni
| Chief Executive Officer | 3 |
| President | 3 |
| Director/Board Member | 2 |
Settori
| Consumer Services | 4 |
| Health Technology | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| APREA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Health Technology |
Atrin Pharmaceuticals, Inc.
Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Health Technology |
- Borsa valori
- Insiders
- Oren Gilad
- Esperienza
